Cortivision

Cortivision is a Swedish neurotechnology company developing innovative solutions for vision restoration in patients with visual impairment caused by retinal and optic nerve diseases. The company has developed a non-invasive visual cortex stimulation device that uses transcranial magnetic stimulation (TMS) to modulate neural activity in the visual cortex and augment remaining visual function. This novel approach targets the brain rather than the eye itself, offering a potential treatment pathway for patients where traditional therapies have limited efficacy.

Based in Gothenburg, Sweden, Cortivision has secured seed funding of $3 million to advance its neuromodulation platform toward clinical validation. The company is positioned at the intersection of neurotechnology and vision restoration, addressing a significant unmet medical need for the millions of people worldwide living with irreversible vision loss from retinal degeneration, age-related macular degeneration, and optic nerve damage. Their TMS-based approach represents a differentiated mechanism compared to competing vision restoration technologies currently in development.

Cortivision's work exemplifies the growing potential of non-invasive neuromodulation to restore lost sensory function, a paradigm shift in how the neurotech industry approaches neurological rehabilitation. By leveraging the brain's neuroplasticity through targeted cortical stimulation, the company demonstrates how precision neurotech can offer therapeutic benefits beyond traditional pharmaceutical or surgical interventions. Success in this space could validate TMS and similar approaches for other sensory and cognitive restoration applications, opening new clinical pathways for millions of patients with acquired neurological deficits.